deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT00630552

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of AMG 655 or AMG 479 in Combination With Gemcitabine as First-Line Therapy for Metastatic Pancreatic Cancer

Sponsor: NantCell, Inc.

Updated 9 times since 2017 Last updated: Oct 14, 2024 Started: Jun 30, 2007 Primary completion: Jan 31, 2010 Completion: Apr 30, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Adenocarcinoma of the Pancreas and Metastatic Pancreatic Cancer and is currently completed. NantCell, Inc. leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2024 · 27 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotCompleted~Nov 2024 – ~Sep 2025 · 10 months · monthly snapshotCompleted~Sep 2025 – present · 7 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Nov 2024 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Completed PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  5. Apr 2022 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

Show 4 earlier versions
  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE1_PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NantCell, Inc.
Data source: NantCell, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .